Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TACE + Axitinib + Hydroxychloroquine for Liver-Dominant Metastatic Colorectal Cancer
NCT04873895Phase 1Terminated
- Sponsor
- Abramson Cancer Center
- Start
- Jan 2022
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of axitinib and hydroxychloroquine in colorectal cancer (CRC), sponsored by Abramson Cancer Center. Primary endpoint: Serious adverse event rate at 12 months. Started Jan 2022; status: terminated.
02
Drugs
axitinibhydroxychloroquine
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT04873895.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04873895.